Company GT Biopharma, Inc.

GTBP

US36254L3087

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:30:26 2024-06-04 am EDT			5-day change	1st Jan Change
3.46 ^USD	-2.95%		-3.40%	-55.42%

May. 21	Top Midday Decliners	MT
May. 21	GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	MT

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.

The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).

Managers	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	61	21-01-12
Manu Ohri DFI	Director of Finance/CFO	68	22-02-17
Jeffrey Miller PRN	Corporate Officer/Principal	-	22-12-13

Members of the board	Title	Age	Since
Charles Casamento BRD	Director/Board Member	78	23-04-30
Bruce Wendel BRD	Director/Board Member	70	20-11-10
Rajesh Shrotriya BRD	Director/Board Member	79	21-01-12
Michael Breen CEO	Chief Executive Officer	61	21-01-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	96,230	0	0	89.34 %
Stock B	1	2,156,651	2,012,830 ( 93.33 %)	0

Name	Equities	%	Valuation
DekaBank Deutsche Girozentrale 50.71 %	1,093,645	50.71 %	4 M $
Bristol Capital Advisors LLC 8.810 %	190,000	8.810 %	712 880 $
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 4.259 %	91,860	4.259 %	344 659 $
Armistice Capital LLC 3.362 %	72,511	3.362 %	272 061 $
Michael Breen 1.323 %	28,540	1.323 %	107 082 $
Vanguard Group, Inc. (Subfiler) 0.9511 %	20,512	0.9511 %	76 961 $
BMO Bank NA (Investment Management) 0.9214 %	19,872	0.9214 %	74 560 $
Bruce Wendel 0.5451 %	11,755	0.5451 %	44 105 $
Manu Ohri 0.5409 %	11,666	0.5409 %	43 771 $
Geode Capital Management LLC 0.5186 %	11,184	0.5186 %	41 962 $

GT Biopharma, Inc.

8000 Marina Boulevard Suite 100

94005, Brisbane

+415 919 4040

http://www.gtbiopharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
GT BIOPHARMA, INC.	-55.42%	7.69M
ELI LILLY AND COMPANY	+42.26%	748B
NOVO NORDISK A/S	+33.79%	598B
JOHNSON & JOHNSON	-5.61%	356B
MERCK & CO., INC.	+18.35%	325B
ABBVIE INC.	+4.95%	283B
ASTRAZENECA PLC	+17.60%	245B
NOVARTIS AG	+9.25%	211B
ROCHE HOLDING AG	-4.17%	209B
PFIZER, INC.	+3.07%	166B

Other Pharmaceuticals